Jheng-Sian Li

Title: Jheng-Sian Li: Innovator in Antibody-Drug Conjugates

Introduction

Jheng-Sian Li is a prominent inventor based in Xiluo, Taiwan. He has made significant contributions to the field of biopharmaceuticals, particularly in the development of antibody-drug conjugates (ADCs). His innovative work has the potential to enhance targeted cancer therapies.

Latest Patents

Jheng-Sian Li holds 1 patent for his invention titled "Antibody-drug conjugate (ADC) and method for forming the same." This patent describes an ADC of formula (I) or a pharmaceutically acceptable salt or solvate thereof. In this formula, p is an integer ranging from 1 to 26, A represents an antibody, and -(L-D) is a linker-drug unit. The linker unit, L, contains a glycopeptide, while D is the drug unit. The antibody is conjugated to the linker unit through a cysteine residue of the antibody. This innovative method for forming an ADC is a significant advancement in the field.

Career Highlights

Jheng-Sian Li is affiliated with the Industrial Technology Research Institute, where he continues to push the boundaries of research and development in biopharmaceuticals. His work is characterized by a commitment to improving therapeutic options for patients.

Collaborations

Some of his notable coworkers include Yi-Ju Ko and Maggie Lu. Their collaborative efforts contribute to the success of the projects they undertake together.

Conclusion

Jheng-Sian Li's contributions to the field of antibody-drug conjugates exemplify the innovative spirit of modern science. His work not only advances the understanding of targeted therapies but also holds promise for improving patient outcomes in cancer treatment.